Almac has brought a second stream for High Throughput GMP Peptide manufacturing online.
The High Throughput GMP Peptide facility, based in Edinburgh, Scotland, manufactures neoantigen derived peptides for use in the production of patient specific, individualized cancer vaccines.
Almac has been active in High Throughput manufacturing of neoantigen derived peptides – branded by Almac as NeoPeptides – for several years. The NeoPeptides facility underwent a conversion from non-GMP to GMP through 2018 and has been operating in full GMP mode since September. The facility has undergone a successful MHRA inspection and has now moved into routine GMP supply.
Almac Sciences’ NeoPeptides offering is built upon Almac’s track record in high speed manufacturing of peptides from its Edinburgh facility. The key which has enabled Almac to convert this technical competence into High Throughput GMP manufacturing has been the creation and implementation of a bespoke Pharmaceutical Quality System, designed specifically to enable high speed, fully compliant GMP manufacturing. The company can already stand on its track record; in the first eight weeks of GMP operation the facility manufactured and released >80 GMP peptides.
“Almac’s decision to bring a second GMP NeoPeptides manufacturing stream online so quickly after the first is a clear statement of our commitment to the field of individualized cancer vaccines,” Dr. Charles Shields, Vice President Peptides and Small Molecule API said. “We understand this market well and intend to maintain our world leading supply position on neoantigen derived peptides. We will be announcing further expansions of our facility and our service offering in the coming months.”